Module Database Search



MODULE DESCRIPTOR
Module Title
Therapeutics
Reference PHM032 Version 3
Created September 2017 SCQF Level SCQF 11
Approved May 2011 SCQF Points 30
Amended September 2017 ECTS Points 15

Aims of Module
To develop professional competence in therapeutic areas (refer to Note 1 in Additional Notes) with emphasis on rational prescribing.

Learning Outcomes for Module
On completion of this module, students are expected to be able to:
1 Systematically apply knowledge and understanding of pathophysiology, clinical pharmacology and evidence based therapeutics for the specified disorders in a professional manner.
2 Critically evaluate a variety of types of numerical data, including biochemical, haematological, and pharmacokinetic parameters, to aid drug selection and monitoring for individual patients.
3 Systematically utlise evidence to critically evaluate patient data to solve therapeutic problems and synthesise a therapeutic plan that includes the selection, monitoring and counselling of drug therapy for individual patients.
4 Critically review current practice and reflect on individual performance in relation to drug therapeutics.

Indicative Module Content
The module will cover the following aspects of therapeutics for diseases (refer to Note 1 in Additional Notes): DISEASE characteristics: epidemiology, aetiology, pathophysiology, clinical manifestations, signs/symptoms, abnormal results. Use of patient data including physical examination, physiological, biochemical and haematological parameters, to select, optimise and monitor drug therapy for conditions. DRUGS for the diseases: clinical pharmacology, pharmacokinetics THERAPEUTIC PLANNING: evidence based approach to drug selection, monitoring: effectiveness (disease and drugs), toxicity (drugs), counselling. Factors influencing prescribing and selection of therapy decisions including patients' characteristics (elderly, young, pregnant and breast feeding mothers, ethnic origin and co-morbidities), and drug factors (adverse drug reactions, drug interactions), aspects of pharmacokinetics and pharmacodynamics. Management options including non-drug treatment. In particular there will be significant emphasis on the use of evidence to critically evaluate complex patient data to devise the therapeutic plan and the implementation of this plan through communication and liaison with patients and other healthcare professionals. Students will also be encouraged to reflect on their own practice for the body systems outlined above and identify ways to improve performance in each aspect of the therapeutic planning process.

Module Delivery
Online distance learning supported by problem bases study materials including directed reading and contact / structured discussion with peers and academic e-tutor staff.

Indicative Student Workload Full Time Part Time
Contact Hours N/A 30
Non-Contact Hours N/A 270
Placement/Work-Based Learning Experience [Notional] Hours N/A N/A
TOTAL N/A 300
Actual Placement hours for professional, statutory or regulatory body    

ASSESSMENT PLAN
If a major/minor model is used and box is ticked, % weightings below are indicative only [for the purposes of the Key Information Set (KIS)]
Component 1
Type: Coursework Weighting: 50% Outcomes Assessed: 1, 2, 3
Description: Block 2 TMA case study contributing 50% towards the final module grade.
Component 2
Type: Coursework Weighting: 50% Outcomes Assessed: 1, 2, 3
Description: Block 3 TMA case study contributing 50% towards the final module grade.
Component 3
Type: Coursework Weighting: 0% Outcomes Assessed: 4
Description: TWO quality postings to the discussion forums for each therapeutic block and TWO reflective learning accounts. Assessed on a Pass/ Fail basis.

MODULE PERFORMANCE DESCRIPTOR
Explanatory Text
To pass this module, the student must achieve a module Grade of Grade D or better and C3 must be passed.
Module Grade Minimum Requirements to achieve Module Grade:
A When the aggregate mark (expressed as a percentage) obtained for C1 and C2 is 70% or more, with a minimum mark of 40% in both C1 and C2, and C3 is passed.
B When the aggregate mark (expressed as a percentage) obtained for C1 and C2 is 60 - 69 %, with a minimum mark of 40% in both C1 and C2, and C3 is passed.
C When the aggregate mark (expressed as a percentage) obtained for C1 and C2 is 50 - 59 %, with a minimum mark of 40% in both C1 and C2, and C3 is passed.
D When the aggregate mark (expressed as a percentage) obtained for C1 and C2 is 40 - 49 %, with a minimum mark of 40% in both C1 and C2, and C3 is passed.
E When the aggregate mark (expressed as a percentage) obtained for C1 and C2 is 35 - 39 %, and C3 is passed.
F When the aggregate mark (expressed as a percentage) obtained for C1 and C2 is less than 35% AND/OR C3 is not passed.
NS Non-submission of work by published deadline or non-attendance for examination

Module Requirements
Prerequisites for Module An undergraduate degree in a pharmacy, from a UK university or overseas equivalent, at a minimum of honours level and one years post-registration experience OR an integrated masters degree in pharmacy (MPharm) and professional registration OR in consultation with the Course Leader.
Corequisites for module None.
Precluded Modules None.

ADDITIONAL NOTES
1. This module is studied as three blocks, two blocks of core topics and one block of elective topics as detailed below. Core topics: Cardiovascular - including hypertension, chronic cardiac failure, ischaemic heart disease, hyperlipidaemia Endocrine - including diabetes mellitus, thyroid disorders Respiratory - including asthma, chronic obstructive pulmonary disease Musculoskeletal - including osteoarthritis, rheumatoid arthritis, pain Infections - including, antimicrobial resistance, respiratory tract infections Elective Topics: Oncology/haematology Psychiatry/neurological conditions Gastrointestinal diseases General medical conditions 1 - stroke, atrial fibrillation General medical conditions 2 - HIV infection, tuberculosis

INDICATIVE BIBLIOGRAPHY
1 HASLETT, C. et al., current edition. Davidson's Principles and Practice of Medicine. London: Churchill Livingston.
2 BRITISH MEDICAL ASSOCIATION AND ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN., current edition. British National Formulary. London: BMJ Publishing Group.

 

Robert Gordon University, Garthdee House, Aberdeen, AB10 7QB, Scotland, UK: a Scottish charity, registration No. SC013781